Zepbound Side Effects: The GI Symptoms, the Mood Question, and What's Actually Serious

What are the most common Zepbound side effects in women?

Tirzepatide, the active ingredient in Zepbound, activates two hormonal pathways at once — GLP-1 and GIP — that together slow how fast your stomach empties and quiet appetite signaling in the brain. Almost everything on the everyday side-effect list is that mechanism working as intended, not a sign that something has gone wrong.

• Nausea — the single most common complaint, strongest in the days right after each dose increase
• Diarrhea — reported by a meaningful minority, sometimes alternating with constipation at different points in treatment
• Constipation — often shows up later in a dose cycle than the nausea does
• Vomiting — less frequent than nausea, more likely early on
• Decreased appetite, mild abdominal pain, or reflux
• Fatigue or headache, particularly when food intake drops sharply
• Injection-site redness or irritation

In the trials that supported Zepbound's approval, nausea affected roughly a quarter to just under a third of people, depending on dose — 25% at 5mg, 29% at 10mg, and 28% at 15mg. Placebo, by comparison, sat at 8%. Diarrhea followed a similar shape, running from 19% up to 23% across those same doses, also well above the 8% placebo rate. Vomiting and constipation ran lower, roughly in the high single digits to upper teens depending on dose, and both stayed well above what placebo groups reported.

Zoomed out, some gastrointestinal symptom showed up in 56% of people on Zepbound at every dose studied, compared with 30% on placebo. Most of that gap traces back to the dose-escalation weeks specifically — the majority of nausea, vomiting, and diarrhea events happened during a dose increase and eased as the following weeks passed. A small share of people stop the medication entirely over GI symptoms — about 2% at the lowest dose, climbing to roughly 4% at the highest. Placebo's discontinuation rate stayed under 1% by comparison. That means the overwhelming majority of people who get these symptoms stay on treatment through them.

Does Zepbound cause depression, or make mood worse?

This is the question this guide is built to answer carefully, because the honest answer has actually shifted meaningfully in the last two years. What gets reported anecdotally is real enough — some people describe irritability, a flatter mood, or a new undercurrent of anxiety after starting Zepbound. What's less settled is whether the drug itself causes that, versus other things happening alongside it.

Here's the regulatory history, because it matters for how much weight to put on this. In July 2023, the FDA opened an investigation into postmarketing reports of suicidal thoughts and behavior linked to GLP-1 medications, tirzepatide included, and the drugs' labels carried a caution about that risk while the review continued. A preliminary January 2024 statement said the evidence so far didn't show these medicines caused suicidal thoughts or actions. The full review has now finished: in a drug safety communication dated January 13, 2026, the FDA reported finding no increased risk of suicidal ideation or behavior across a meta-analysis of 91 clinical trials covering more than 107,000 patients, plus a separate retrospective study of 2.2 million real-world users. That same review also looked specifically at anxiety, depression, irritability, and psychosis, and found no increased risk there either. The FDA is now asking that the warning be removed from the labels of Zepbound, Wegovy, and Saxenda.

That's a genuinely reassuring finding, and it's worth taking at face value rather than assuming there's still an open question the drug companies are quietly sitting on. It doesn't mean nobody on Zepbound ever feels low or anxious — it means the evidence doesn't point to tirzepatide as the direct cause when that happens. A few things plausibly explain the mood symptoms some people do report: eating dramatically less than usual is its own stress on the body and brain, nausea or reflux bad enough to disrupt sleep will flatten anyone's mood within days, and rapid weight loss itself, independent of the drug producing it, is associated with mood changes in some people. None of that is the same claim as "tirzepatide is a depressant."

If you're in perimenopause, there's a second layer worth naming honestly: declining and fluctuating estrogen already affects mood regulation on its own, with no medication involved. A new low mood or anxious stretch that starts during Zepbound treatment could be the transition running its own course in parallel, not something the drug introduced. Perimenopause depression walks through that mechanism and what actually helps if it's the more likely explanation.

Can Zepbound cause mood swings — or actually help with anxiety?

Mood swings aren't listed as their own separate item on Zepbound's adverse-reaction table the way nausea or diarrhea are, but a lot of what produces a mood swing is downstream of things that are on that list. A big appetite drop changes your blood sugar rhythm and your relationship to food within the same day, and that kind of shift can leave you feeling unusually irritable or flat for a few hours without any deeper cause. People describe it in both directions online — some feel calmer around food than they have in years, others describe a new low-grade dread on dosing day itself.

There's no established pharmacologic mechanism by which tirzepatide reduces or worsens anxiety directly, so neither of those anecdotal patterns should be read as the drug's guaranteed effect on you. A useful way to sort your own experience: a mood dip that shows up specifically in the day or two after a dose and fades within 48 to 72 hours points toward the GI-and-appetite mechanism above. A mood shift that tracks with your cycle, or shows up alongside hot flashes and night sweats regardless of when you last dosed, points more toward perimenopause running underneath it — perimenopause anxiety covers that mechanism and what's actually shown to help.

Does Zepbound cause hair loss?

There's no known mechanism by which tirzepatide acts on hair follicles directly, and that's worth saying plainly before the numbers below, since it's easy to read a real statistic as proof of a direct drug effect it isn't. What actually happens, in the people who experience it, is telogen effluvium — a temporary, diffuse shedding pattern that follows any sufficiently fast weight loss, whatever caused it. Losing weight quickly pushes more hair follicles than usual out of their growth phase and into a resting phase at the same time, and months later that resting hair sheds together instead of gradually.

In Zepbound's own trial program, alopecia was reported in roughly 5% of people on the drug, against about 1% on placebo — a real, documented difference large enough that it's listed as an adverse reaction on the FDA label. It also isn't evenly distributed by sex: pooled data across the trials found alopecia reported at 7.1% among women, compared with 0.5% among men, which lines up with women also losing meaningfully more weight on average in these trials. More effect, more shedding — not a sign the drug behaves differently or more dangerously in a woman's body.

Timing tends to be predictable: shedding usually starts a few months after your fastest stretch of weight loss, not right when you begin the medication, which is part of why it catches people off guard. For most people it's self-limiting — once weight stabilizes, hair density typically recovers over the following months. If you're also noticing perimenopausal thinning on top of this, perimenopause hair loss untangles that separate, hormonally driven mechanism.

Is Zepbound safe — and how does it compare to Mounjaro's side effects?

Zepbound and Mounjaro are the same molecule, tirzepatide, on the same dose ladder — both climb from a 2.5mg starting dose up to a 15mg ceiling. Because the drug itself is identical, the core side-effect profile is essentially identical too: the same GI symptoms in roughly the same proportions, the same boxed warning, the same serious-risk list below. What actually differs is the FDA-approved indication. Zepbound is approved for chronic weight management — obesity, being overweight with a weight-related condition, or moderate-to-severe obstructive sleep apnea alongside obesity. Mounjaro is approved for type 2 diabetes. If a prescriber writes you Mounjaro specifically for weight loss rather than diabetes, that's off-label use of the same molecule, not a different or less-tested drug.

For most healthy adults, that means the common side effects above are frequent but manageable, and the serious risks covered next are uncommon. The bigger safety-adjacent question for most people is less about the molecule itself and more about which regulatory pathway — brand-name Zepbound, off-label Mounjaro, or a compounded version — you're comfortable navigating, since compounded tirzepatide sits on notably different legal footing than either brand.

What are Zepbound's serious side effects — pancreatitis, gallbladder disease, thyroid tumors, cancer?

A shorter, less common list of risks sits underneath the everyday GI complaints, and it's the reason Zepbound carries the warnings it does.

• Thyroid C-cell tumors — Zepbound carries a boxed warning based on a two-year rodent study, where tirzepatide caused a dose- and duration-dependent increase in thyroid C-cell tumors at clinically relevant exposures. Whether this translates to humans hasn't been established, and Zepbound is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Patients are counseled to watch for a lump or swelling in the neck, persistent hoarseness, or trouble swallowing
• Pancreatitis — including rare fatal and non-fatal severe cases, has been observed in people treated with GLP-1 receptor agonists including tirzepatide. The drug hasn't been studied in people with a prior history of pancreatitis, and a personal history typically steers a prescriber toward a different option
• Gallbladder disease — rapid weight loss on its own raises the risk of gallstones forming, and gallbladder-related events, including in some cases gallbladder removal surgery, were reported more often among people on Zepbound than on placebo in the pivotal trials. That risk traces more to the pace of weight loss itself than to a direct toxic effect of the drug

On the direct cancer question, worth answering plainly because it gets flattened online into something broader than it is: no confirmed human case of thyroid C-cell tumors tied to tirzepatide has been reported to date, and the boxed warning is specifically about the rare medullary thyroid cancer subtype seen in rodents, not a signal about the far more common thyroid cancer types that make up most real-world diagnoses. Longer-term cancer questions across the whole GLP-1/GIP drug class remain an area of ongoing research rather than a fully closed one, which is a fair thing to hold as an open question rather than resolving into false certainty in either direction.

Which Zepbound side effects mean call a doctor the same day?

The everyday nausea-and-bloating cluster from earlier is one category. This is a different one — symptoms that overlap with the serious risks above and are worth same-day attention rather than a routine follow-up message.

• Severe, persistent abdominal pain, especially if it radiates to your back, with or without vomiting — a possible sign of pancreatitis
• Pain in the upper right abdomen, fever, or yellowing of the skin or eyes — possible gallbladder involvement
• A new lump or swelling in your neck, persistent hoarseness, or trouble swallowing — the symptoms tied to the thyroid warning
• Signs of severe dehydration — very reduced urination, dizziness on standing, confusion — especially after several days of vomiting or diarrhea
• Severe low blood sugar if you also take insulin or a sulfonylurea — shakiness, confusion, sweating that doesn't resolve with food
• New or worsening depression, hopelessness, or any thoughts of self-harm — worth reporting the same day even though current evidence doesn't tie tirzepatide to causing these, because you deserve support regardless of the cause

Are Zepbound's side effects different for women in perimenopause?

The alopecia gap above — 7.1% in women versus 0.5% in men across pooled trial data — is the clearest sex-specific figure that exists for this drug, and it tracks with women also losing more weight on average rather than suggesting Zepbound behaves less safely in a woman's body. Past that one number, most of what makes side effects harder to sort out in perimenopause isn't a different drug reaction — it's two symptom sets running at the same time.

Fatigue, disrupted sleep, and stomach upset already show up during the menopause transition with no medication involved, so a woman starting Zepbound in her 40s or 50s is untangling two overlapping causes rather than one. Night sweats that wake you up, combined with nausea that also wakes you up, add up to exhaustion that's genuinely hard to attribute to either cause alone. A rough rule of thumb: GI symptoms that track tightly with your dose increases and ease within a week or two are more likely Zepbound; fatigue or mood shifts that show up independent of dosing, or alongside hot flashes and cycle changes, more likely trace back to the transition itself.

Muscle is the other place these two things compound each other. Perimenopause already erodes lean mass on its own as estrogen declines, and Zepbound's weight loss includes a real share of muscle alongside fat — more on that next. Losing muscle from two directions at once is the part of this that deserves the most deliberate counter-strategy, not the GI symptoms most people worry about first.

What are Zepbound's long-term side effects — muscle loss, bone density, and what happens after stopping?

In the body-composition sub-study of Zepbound's pivotal trial, people on the drug lost 10.9% of their lean mass by week 72, compared with 2.6% on placebo. Proportionally, roughly three-quarters of the weight lost was fat and one-quarter was lean mass in both groups — a ratio that held steady whether someone was on the drug or on placebo. What differs is the total amount of weight lost: because Zepbound produces so much more overall weight loss than placebo, that same one-quarter share adds up to a much larger absolute amount of muscle gone. That distinction matters more after 40, when perimenopause is already working against the same tissue — GLP-1s and muscle loss in perimenopause covers the research in depth and what actually protects muscle during treatment.

Bone density is a genuinely thinner research area. Zepbound's own FDA label doesn't currently include bone density or fracture-risk data. Separate research looking at both semaglutide and tirzepatide in people already at elevated fracture risk found measurable reductions in hip and spine bone density that scaled roughly with how much weight someone lost — a plausible mechanical effect of less load-bearing weight on bone, rather than a signal specific to this drug class. It's an open question being actively studied, not a settled label warning.

On stopping: a follow-up study that switched people from tirzepatide to placebo after roughly nine months on the drug found they regained an average of 14% of their body weight over the following year, alongside a partial reversal of the metabolic improvements they'd gained. Even so, that group ended the study still meaningfully ahead of where they started — nowhere near back to baseline. The honest takeaway is that Zepbound's benefits are tied to staying on it, which is worth factoring into a long-term plan rather than a surprise a year or two in.

How do you manage Zepbound side effects day to day?

A handful of practical habits cover most of what shows up in the first weeks and months.

• Respect the titration schedule — dose increases are spaced out specifically to give your gut time to adjust; asking to move faster tends to backfire
• Go smaller and lower-fat with meals — Zepbound already slows digestion, and a large or fatty meal on top of that is the most common nausea trigger
• Stay ahead of hydration, especially during a rough stretch of vomiting or diarrhea
• Prioritize protein at each meal — it supports satiety and helps protect lean muscle during a period of reduced overall intake
• Rotate your injection site each week — thigh, abdomen, back of the arm — rather than reusing the same spot
• Track when nausea tends to peak after a dose — some people do better adjusting meal timing or injecting at a specific time of day once they notice their own pattern

Where to get Zepbound with support if a side effect isn't settling

If a symptom is dragging past the first couple of months, or you'd rather have labs confirm what's going on than guess, the real differences between programs show up less in the sticker price and more in what's already bundled once you're enrolled.

Ro Body is a branded-only program — it doesn't dispense compounded semaglutide or tirzepatide at all, only FDA-approved Wegovy, Zepbound, and Ozempic. Its membership bundles labs, coaching, and insurance navigation into one monthly fee, separate from Zepbound's own $299 to $449 self-pay ladder by dose — useful specifically if a side effect needs a blood panel rather than a guess, since that's already accounted for in the membership rather than a new bill.

If cost is the binding constraint and you're weighing a compounded alternative instead of brand Zepbound, Mochi Health, Henry Meds, and Fridays all dispense compounded tirzepatide rather than the Zepbound brand itself — the same active molecule, prepared by a licensed pharmacy rather than manufactured by Eli Lilly, which is worth knowing plainly before you switch. Mochi keeps its medication price flat at every dose, which helps specifically if a provider slows your titration to manage a side effect. Henry Meds is one of the few offering a genuine oral tablet alongside the injection. Fridays bundles dietitian and coaching access, useful if appetite changes are making meal planning genuinely hard.